세계의 항비만 처방약 시장 : 약제 클래스별, 연령층별, 유통 채널별 - 예측(2025-2030년)

The Anti-obesity Prescription Drugs Market was valued at USD 6.22 billion in 2023, expected to reach USD 6.71 billion in 2024, and is projected to grow at a CAGR of 8.12%, to USD 10.74 billion by 2030.

Anti-obesity prescription drugs are specialized pharmaceuticals designed to aid in weight loss by altering metabolic or appetite-regulating pathways. The necessity for these medications arises from the global obesity epidemic, which is associated with severe health complications such as diabetes, cardiovascular diseases, and certain cancers. Their application predominantly targets individuals with a body mass index (BMI) of 30 or higher, or those experiencing obesity-related conditions. The predominant end-users include healthcare facilities, clinics, and pharmacies, with a growing interest from wellness centers and telemedicine platforms.

The market for anti-obesity drugs is influenced by a rise in obesity rates and increasing awareness of the health risks associated with obesity, fueling demand for effective treatment options. Technological advancements in drug formulation and delivery, along with government supportive initiatives and research funding, further stimulate market growth. Opportunities lie in expanding into emerging markets where obesity rates are climbing, and there are unmet medical needs. Collaborative efforts between pharmaceutical companies and digital health startups to provide comprehensive weight management solutions represent another promising avenue. Yet, market growth is challenged by high R&D costs, stringent regulatory approvals, and potential side effects associated with long-term drug use, which can result in patient reluctance and limited adherence.

Innovation is pivotal in addressing these challenges, with potential areas including the development of personalized medicine tailored to genetic profiles and the integration of AI and big data to enhance drug efficacy and patient compliance. Additionally, exploring combination therapies that utilize multiple mechanisms to enhance weight loss outcomes can differentiate market offerings. Overall, the nature of the anti-obesity drug market is dynamic, with vast potential for growth as trends shift towards holistic healthcare solutions. Businesses that invest in robust clinical trials and consider diverse market needs are likely to thrive, maximizing both public health benefits and economic returns.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-obesity Prescription Drugs Market

The Anti-obesity Prescription Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of obesity and related chronic diseases
  • Growing unhealthy and sedentary lifestyle
  • Advancement in medical research by drug-manufacturing companies, medical universities and institutes, and government agencies
• Market Restraints
  • Side effect related to anti-obesity drugs
• Market Opportunities
  • Introduction of novel anti-obesity drugs
  • Accelerating awareness towards obesity management
• Market Challenges
  • Availability of alternative treatment options

Porter's Five Forces: A Strategic Tool for Navigating the Anti-obesity Prescription Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-obesity Prescription Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-obesity Prescription Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-obesity Prescription Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-obesity Prescription Drugs Market

A detailed market share analysis in the Anti-obesity Prescription Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-obesity Prescription Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-obesity Prescription Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-obesity Prescription Drugs Market

A strategic analysis of the Anti-obesity Prescription Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-obesity Prescription Drugs Market, highlighting leading vendors and their innovative profiles. These include Alisier Drugs Pvt. Ltd., Arena Pharmaceuticals Ltd, Arrowhead Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Currax Pharmaceuticals LLC, Eisai Co., Ltd, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Norgine BV, Novo Nordisk A/s, SHIONOGI & Co., Ltd., Takeda Pharmaceutical Company Limited, VIVUS LLC, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Anti-obesity Prescription Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Class, market is studied across Bupropion & Naltrexone, Liraglutide, Lorcaserin, Orlistat, and Phentermine & Topiramate.
• Based on Age Group, market is studied across Adult and Pediatric.
• Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of obesity and related chronic diseases
    • 5.1.1.2. Growing unhealthy and sedentary lifestyle
    • 5.1.1.3. Advancement in medical research by drug-manufacturing companies, medical universities and institutes, and government agencies
  • 5.1.2. Restraints
    • 5.1.2.1. Side effect related to anti-obesity drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Introduction of novel anti-obesity drugs
    • 5.1.3.2. Accelerating awareness towards obesity management
  • 5.1.4. Challenges
    • 5.1.4.1. Availability of alternative treatment options
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Anti-obesity Prescription Drugs Market, by Drug Class

• 6.1. Introduction
• 6.2. Bupropion & Naltrexone
• 6.3. Liraglutide
• 6.4. Lorcaserin
• 6.5. Orlistat
• 6.6. Phentermine & Topiramate

7. Anti-obesity Prescription Drugs Market, by Age Group

• 7.1. Introduction
• 7.2. Adult
• 7.3. Pediatric

8. Anti-obesity Prescription Drugs Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacy
• 8.3. Online Pharmacy
• 8.4. Retail Pharmacy

9. Americas Anti-obesity Prescription Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Anti-obesity Prescription Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Anti-obesity Prescription Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Alisier Drugs Pvt. Ltd.
• 2. Arena Pharmaceuticals Ltd
• 3. Arrowhead Pharmaceuticals, Inc.
• 4. Boehringer Ingelheim International GmbH
• 5. Bristol-Myers Squibb Company
• 6. Currax Pharmaceuticals LLC
• 7. Eisai Co., Ltd
• 8. F. Hoffmann-La Roche AG
• 9. GlaxoSmithKline PLC
• 10. Norgine BV
• 11. Novo Nordisk A/s
• 12. SHIONOGI & Co., Ltd.
• 13. Takeda Pharmaceutical Company Limited
• 14. VIVUS LLC
• 15. Zydus Lifesciences Limited